$200,000 of SOLVENTUM CORPORATION lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"-Issues related to Department of Defense policy, procurement, and contracting processes for medical technology. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to domestic and global medical supply chain resilience. -Tariff issues generally. -Issues related to the 232 investigation of imports of Personal Protective Equipment, Medical Consumables, and Medical Equipment, Including Devices. -Issues related to Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure to Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced with Forced Labor. Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology. -Issues related to regulation of Ethylene Oxide (EtO). -Issues related to access to sterilization capacity for medical technologies. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act. -Implementation of the 21st Century Cures Act (PL 114-255). -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS. -Issues related to CY 2027 Outpatient Prospective Payment System Rule Update for Skin Substitutes. -Issues related to MDUFA reauthorization. -Medicare and Medicaid payment quality programs and policies, including healthcare associated complications, readmissions, payment bundling, potentially avoidable events, quality outcomes, transparency, telehealth, health equity, social determinants of health, maternal mortality, risk adjustment, Medicare Advantage, value-based payment policies, and Medicare and Medicaid data. -VA provider coding system modernization. -Implementation of the Patient Protection and Affordable Care Act (PL 111-148). -Implementation of the Helping Hospitals Improve Patient Care Act. -Implementation of the 21st Century Cures Act (PL 114-255). -Issues related to the use of Artificial Intelligence. -Issues related to H.R. 1 implementation (One Big Beautiful Bill). -Issues related to CY 2026 Home Health Prospective Payment System (HH PPS) Rate Update and DMEPOS. -Issues related to CY 2027 Outpatient Prospective Payment System Rate Update for Skin Substitutes."
You can find more data on corporate lobbying on Quiver Quantitative.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
